FDA Approves Wainua: AstraZeneca's Eplontersen for hATTR-PN

The U.S. Food and Drug Administration (FDA) has granted eplontersen (Wainua) approval, marking a significant advancement in the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). This FDA eplontersen approval provides a new therapeutic option for patients affected by this rare, progressive, and fatal disease. Developed by AstraZeneca, Wainua addresses the underlying cause of hATTR-PN by reducing the production of transthyretin (TTR) protein.

Drug Overview

Eplontersen (Wainua) is an antisense oligonucleotide designed to reduce the hepatic production of transthyretin (TTR) protein. It is indicated for the treatment of Hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), a rare, progressive, and fatal disease caused by mutations in the TTR gene leading to amyloid fibril deposition. The drug works by selectively binding to TTR mRNA, promoting its degradation and thereby reducing the amount of TTR protein produced in the liver.

Clinical Insights

Eplontersen (Wainua) has been evaluated in a Phase III clinical trial. The primary endpoint was the Neuropathy Impairment Score (NIS). Clinical trials demonstrated improvement in neuropathy impairment scores and quality of life measures (Norfolk QOL-DN) over a period of 12-18 months. Observed adverse events included injection site reactions, thrombocytopenia, renal function changes, and potential liver enzyme elevations.

Regulatory Context

Drugs for rare diseases like hATTR-PN often follow expedited FDA pathways such as Orphan Drug Designation, Fast Track, and Priority Review to accelerate approval based on surrogate or clinical endpoints demonstrating meaningful benefit. Class-typical adverse events for antisense oligonucleotides include injection site reactions, thrombocytopenia, renal function changes, and potential liver enzyme elevations. Monitoring protocols are standard in clinical use.

Market Impact

The approval of eplontersen (Wainua) enters a market where existing treatments for hATTR-PN include tafamidis, patisiran, and inotersen. With an estimated 5,000-10,000 patients in the US, the drug may provide a differentiated treatment option with potentially more convenient subcutaneous dosing and competitive safety profile versus existing TTR stabilizers and RNA interference therapies. Eplontersen's antisense oligonucleotide mechanism and subcutaneous administration may offer improvements in dosing convenience and safety compared to tafamidis, patisiran, and inotersen.

Future Outlook

Future developments for eplontersen (Wainua) may include exploring label expansions and combination trials to further enhance its therapeutic potential in treating hATTR-PN. Further studies may also focus on long-term safety and efficacy data to solidify its position in the treatment landscape.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-05.

Dr. Sarah Chen MD, PhD, FACP

Senior Medical Editor

Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...

📅 Published: April 05, 2026